Radiopharmaceutical developer Aktis Oncology completed a Nasdaq IPO that raised about $318 million, marking the first biotech public offering of 2026. The company plans to use proceeds to advance its miniprotein radioconjugates, including Ac‑AKY‑1189 targeting Nectin‑4 and a second candidate for B7‑H3 expressing tumors, and to fund ongoing Phase 1b studies and imaging‑guided patient selection programs. Aktis highlighted prior strategic partnerships, including a purchase by Eli Lilly in the offering. The IPO upsized pricing and drew industry attention because radiopharma remains an acquisition and partnership focus for big drugmakers. Aktis said the capital will support dose‑escalation and expansion cohorts and to move toward tumour‑targeted imaging companion diagnostics to select likely responders.